Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Just bought at 70.836 - showing as sell
Something is happening: 11-Sep-23 13:06:20 1,458.80 17,975 Buy* 1,458.40 1,459.00 262.22k !
My buy at 15-Jun-23 12:43:15 shows as a sell; my guess is a lot of the sells are actually buys.
I made two sells at 14.125p both of which were shown as buys. All adjacent LSE 'buys' were at that or close prices and were, in my opinion, sells.
I wonder if it is the threat of actions in the USA regarding Zantac and cancer? Whilst the previous cases were rightly thrown out by the judge perhaps the next lot, and it runs into thousands of people, could be based upon science that confirms a causal link rather than a simple association. That said it will drag on for years during which time the new drugs being approved around the world should ensure that GSK has or will have reserves set aside for a worst case scenario.
Would someone explain why the value of the silver is not included?
As it's Christmas, good cheer and all that, I propose that the reduction in share price is to allow employees and locals to buy shares at a ridiculously cheap price - as I think was the case earlier this year when there were a lot of small buys. This is because of the good news round the corner which the management know is coming.
Well why not - let's be positive.
But as always remember Warren Buffet: "The stock market is a device for transferring money from the impatient to the patient"
08:57:13 this morning, bought 3,500 @ 110.624 through Hargreaves; showing as a sell. Several other 'sells' at or around this price probably buys.
Today's grant of awards under the Long Term Incentive Plan in the form of nil-cost options, should give the Director's an incentive to get the SP moving in the right direction. But I guess a lot is out of their control given the current negative factors affecting the economy. Certainly one to stick with until the good times return - ever the optimist!
Astericos now holding 26.27%. Continuing to purchase small quantities, a few thousand here and there. The very wide spread today (501 - 514) and very few trades showing, could indicate a lack of liquidity so perhaps Astericos buying as shares become available on the market. Together with the director buy, certainly looks like something brewing but what, who knows - as ever, DYOR.
Strange how on two successive Wednesdays, sales volume has been very high, much higher than normal (63 & 79 million shares traded respectively against a daily average of around 13 million) and the SP has risen sharply after each Wednesday. Looks like major stake building to me. Would Unilever get HLN for a lot less than the 50 billion (42 billion being cash) offered a year ago? At that time the offer was ridiculed by many financial 'experts' in view of the negative effect it would have had on Unilever. Any sensible thoughts?
Remember 'The stock market is a device for transferring money from the impatient to the patient' Warren Buffet
Anyone have any thoughts on the 62+ million traded last Wednesday, 30th November according to the 3 Month Haleon Share Graph, after which sharp rise in SP so possibly a buy?
A very interesting set of Interim results which need to be read very carefully without concentrating on the forward looking statement:
As noted previously, it has not been possible to complete an equity raise at this current time. The Board will continue to explore alternative funding mechanisms and note that in the absence of any further financing, the Group's current financial resources will be sufficient to support operations until at least the start of the fourth calendar quarter 2023. The Board therefore considers it appropriate to continue to adopt the going concern basis in the preparation of these interim financial statements. However, there is no guarantee that future attempts to secure adequate additional revenues/funding on a timely basis will be successful and, therefore, this represents a material uncertainty, which may cast significant doubt about the Group's ability to continue as a going concern. These interim financial statements do not include the adjustments that would result if the Group were unable to continue as a going concern.
Set this against another forward looking statement;
Fosun Pharma
· In July 2022, a Supplemental Terms Agreement was signed with Fosun Pharma for the Technology Transfer of CTX into China, highlighting continued progress with the collaboration
· The Group expects to receive approximately £1 million over the 24 month period from signing the agreement, of which £320,000 has been received. In addition there is potential under the Technology Transfer agreement for the Group to receive up to £5 million over the medium to long term, with further potential milestone payments of up to £74 million linked to the main agreement signed in 2019.
... and the financials that don't look bad enough to warrant today's drop to 16p (as I write).
Nice to see 4 Director buys on the 30th November. They must know something!
If £0.67 is 4.8% then 100% is indeed £13.81!